Sirius Genomics preps for sepsis research

There is only one approved treatment for sepsis on the market: activated protein C. But due to potential side effects, activated protein C isn't universally prescribed. Sirius Genomics hopes to help determine which cases should receive activated protein C via an international sepsis study.

Sirius is searching for genetic markers that will help predict a patient's likelihood of experiencing activated protein C's adverse side effects. Since the treatment can increase patient survival rates by 13%--normally 30% to 50% of sepsis patients die, with 18 million cases worldwide annually--a biomarker test could help determine which patients will benefit the most from activated protein C treatment.

"This study is unique because we have attracted the top clinical researchers in the world to participate," said Chris Wagner, president and CEO at Sirius Genomics, in a release. "Our common goal is to determine whether there is a genetic marker for positive response to treatment with activated protein C. Doctors can then run a simple test before prescribing the drug to ensure a patient with sepsis will benefit from treatment."

- read the Sirius release

Suggested Articles

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.